Hemeda Dalia Mohamed, El-Mesery Ahmed, Mohamed Mie Ali, Ahmed Gawesh Zeinab Mohammed, Elnahas Waleed, Soliman Mahmoud Abdel-Aziz
Department of Tropical Medicine, Mansoura University, Mansoura, Egypt.
Department of Pathology, Faculty of Medicine, Mansoura University, Egypt.
Asian Pac J Cancer Prev. 2025 Apr 1;26(4):1429-1439. doi: 10.31557/APJCP.2025.26.4.1429.
Preoperative assessment of colorectal cancer requires a multimodal approach including clinical, radiographic, biochemical and colonoscopic assessment with histologic review of biopsies that provides valuable information regarding tumor grading and other significant prognostic factors that aid in determination of the appropriate treatment. The association between Musashi-2 expression and clinicopathological features and its prognostic significance in CRC patients is still controversial. Our study is designed to investigate the expression and prognostic significance of MSI2 and CD163+Tumor associated macrophages in colorectal cancer patients.
Prospective longitudinal study was designed including 114 CRC cases from Tropical Medicine Department and Oncology Center, Mansoura University Hospitals, during the period from July 2021 to October 2024, all cases were diagnosed by colonoscopy then underwent radical surgery with biopsies which were examined by IHC staining for MSI2 and CD163+TAM using tissue microarray technique trying to find out their correlation with clinicopathological parameters and patients prognosis.
Among 114 CRC cases, high MSI2 expression was detected in 49 (43%). MSI2 expression was significantly related to grade of differentiation (P = 0.001*), depth of invasion (P = 0.001*), lymph node metastasis (P = 0.001*), TNM stage (P = 0.001*) and hepatic metastasis (P = 0.009*). Multivariate analysis spotted MSI2 expression as a predictor for Overall survival in CRC (P = 0.015*) and disease free survival (P = 0.008*). CD163+TAM showed a significant correlation to grade of differentiation (P = 0.001*), depth of invasion (P = 0.05*), lymph node metastasis (P = 0.001*), TNM stage (P = 0.001*), and hepatic metastasis (P = 0.007*). Multivariate analysis spotted CD163+TAM expression as a predictor for OS in CRC (P = 0.037*) and DFS (P = 0.003*).
MSI2 and CD163+TAM are independent prognostic factors for the overall survival and disease free survival and can predict poor prognosis in CRC patients.
结直肠癌的术前评估需要采用多模式方法，包括临床、影像学、生化和结肠镜检查评估，并对活检组织进行组织学检查，以提供有关肿瘤分级和其他重要预后因素的有价值信息，从而有助于确定合适的治疗方案。Musashi-2表达与临床病理特征之间的关联及其在结直肠癌患者中的预后意义仍存在争议。我们的研究旨在调查MSI2和CD163+肿瘤相关巨噬细胞在结直肠癌患者中的表达及其预后意义。
设计了一项前瞻性纵向研究，纳入了2021年7月至2024年10月期间曼苏拉大学医院热带医学科和肿瘤中心的114例结直肠癌病例。所有病例均经结肠镜检查确诊，然后接受根治性手术，并通过组织芯片技术对活检组织进行免疫组化染色，检测MSI2和CD163+肿瘤相关巨噬细胞，试图找出它们与临床病理参数和患者预后的相关性。
在114例结直肠癌病例中，49例（43%）检测到高MSI2表达。MSI2表达与分化程度（P = 0.001*）、浸润深度（P = 0.001*）、淋巴结转移（P = 0.001*）、TNM分期（P = 0.001*）和肝转移（P = 0.009*）显著相关。多因素分析发现MSI2表达是结直肠癌总生存期（P = 0.015*）和无病生存期（P = 0.008*）的预测指标。CD163+肿瘤相关巨噬细胞与分化程度（P = 0.001*）、浸润深度（P = 0.05*）、淋巴结转移（P = 0.001*）、TNM分期（P = 0.001*）和肝转移（P = 0.007*）显著相关。多因素分析发现CDI63+肿瘤相关巨噬细胞表达是结直肠癌总生存期（P = 0.037*）和无病生存期（P = 0.003*）的预测指标。
MSI2和CD163+肿瘤相关巨噬细胞是总生存期和无病生存期的独立预后因素，可预测结直肠癌患者的不良预后。
